表紙:世界の医薬品原薬 (API)市場(2021年-2025年)
市場調査レポート
商品コード
986234

世界の医薬品原薬 (API)市場(2021年-2025年)

Global Active Pharmaceutical Ingredients Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
世界の医薬品原薬 (API)市場(2021年-2025年)
出版日: 2021年01月28日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品原薬 (API)の市場規模は、2021年から2025年の間に645億3000万米ドル成長し、予測期間中に6%のCAGRで推移する見込みです。市場は、発展途上国における進化するAPI製造と、コアコンピテンシーに焦点を当てる必要性の高まりによって推進されています。

当レポートでは、医薬品原薬 (API)市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模2020
  • 市場の見通し:2020年から2025年の予測

ファイブフォース分析

製造タイプ別の市場セグメンテーション

  • マーケット・セグメント
  • 製造タイプ別の比較
  • キャプティブAPI-市場規模と予測(2020年~2025年)
  • 契約API-市場規模と予測(2020年~2025年)
  • 製造タイプ別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • アジア太平洋-市場規模と予測(2020年~2025年)
  • 北米-市場規模と予測(2020年~2025年)
  • 欧州-市場規模と予測(2020年~2025年)
  • その他の地域-市場規模と予測(2020年~2025年)
  • 主要な主要国
  • 地域の市場機会
  • 市場の推進力
  • 市場の課題
  • 市場動向

ベンダー情勢

競合シナリオ

ベンダー情勢

創造的破壊の状況

ベンダー分析

対象となるベンダー

ベンダーの市場ポジショニング

Amneal Pharmaceuticals Inc.

カディラヘルスケア株式企業

Dr. Reddy's Laboratories Ltd.

グラクソ・スミスクラインPlc

  • Koninklijke DSM NV
  • マイランNV
  • ノバルティスAG
  • ファイザー株式企業
  • サンファーマ株式企業
  • テバファーマシューティカルインダストリーズリミテッド。

付録

目次
Product Code: IRTNTR40608

Technavio has been monitoring the active pharmaceutical ingredients market and it is poised to grow by $ 64.53 bn during 2021-2025, progressing at a CAGR of 6% during the forecast period. Our report on the active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the evolving API manufacturing scenario in developing countries and the growing need to focus on core competencies. In addition, evolving API manufacturing scenario in developing countries is anticipated to boost the growth of the market as well.

The active pharmaceutical ingredients market analysis includes type segment and geographical landscapes.

Technavio's active pharmaceutical ingredients market is segmented as below:

By Type

Captive APIs

Contract APIs

By Geography

APAC

North America

Europe

ROW

This study identifies the Increasing number of type II DMFs as one of the prime reasons driving the active pharmaceutical ingredients market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the active pharmaceutical ingredients market covers the following areas:

Active pharmaceutical ingredients market sizing

Active pharmaceutical ingredients market forecast

Active pharmaceutical ingredients market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients market vendors that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Manufacturing Type

  • Market segments
  • Comparison by manufacturing type
  • Captive APIs - Market size and forecast 2020-2025
  • Contract APIs - Market size and forecast 2020-2025
  • Market opportunity by manufacturing type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • APAC - Market size and forecast 2020-2025
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

Competitive scenario

Vendor landscape

Landscape disruption

Vendor Analysis

Vendors covered

Market positioning of vendors

Amneal Pharmaceuticals Inc.

Cadila Healthcare Ltd.

Dr. Reddy's Laboratories Ltd.

GlaxoSmithKline Plc

  • Koninklijke DSM NV
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Captive APIs - Market size and forecast 2020-2025 ($ billion)
  • 24: Captive APIs - Year-over-year growth 2020-2025 (%)
  • 25: Contract APIs - Market size and forecast 2020-2025 ($ billion)
  • 26: Contract APIs - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Other1
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: APAC - Market size and forecast 2020-2025 ($ billion)
  • 32: APAC - Year-over-year growth 2020-2025 (%)
  • 33: North America - Market size and forecast 2020-2025 ($ billion)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ billion)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ billion)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ billion)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Amneal Pharmaceuticals Inc. - Overview
  • 48: Amneal Pharmaceuticals Inc. - Business segments
  • 49: Amneal Pharmaceuticals Inc. - Key offerings
  • 50: Amneal Pharmaceuticals Inc. - Key customers
  • 51: Amneal Pharmaceuticals Inc. - Segment focus
  • 52: Cadila Healthcare Ltd. - Overview
  • 53: Cadila Healthcare Ltd. - Business segments
  • 54: Cadila Healthcare Ltd. - Key offerings
  • 55: Cadila Healthcare Ltd. - Key customers
  • 56: Cadila Healthcare Ltd. - Segment focus
  • 57: GlaxoSmithKline Plc - Overview
  • 58: GlaxoSmithKline Plc - Business segments
  • 59: GlaxoSmithKline Plc - Key offerings
  • 60: GlaxoSmithKline Plc - Key customers
  • 61: GlaxoSmithKline Plc - Segment focus
  • 62: Koninklijke DSM NV - Overview
  • 63: Koninklijke DSM NV - Business segments
  • 64: Koninklijke DSM NV - Key offerings
  • 65: Koninklijke DSM NV - Key customers
  • 66: Koninklijke DSM NV - Segment focus
  • 67: Mylan NV - Overview
  • 68: Mylan NV - Business segments
  • 69: Mylan NV - Key offerings
  • 70: Mylan NV - Key customers
  • 71: Mylan NV - Segment focus
  • 72: Novartis AG - Overview
  • 73: Novartis AG - Business segments
  • 74: Novartis AG - Key offerings
  • 75: Novartis AG - Key customers
  • 76: Novartis AG - Segment focus
  • 77: Pfizer Inc. - Overview
  • 78: Pfizer Inc. - Business segments
  • 79: Pfizer Inc. - Key offerings
  • 80: Pfizer Inc. - Key customers
  • 81: Pfizer Inc. - Segment focus
  • 82: Sun Pharmaceutical Industries Ltd. - Overview
  • 83: Sun Pharmaceutical Industries Ltd. - Business segments
  • 84: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 85: Sun Pharmaceutical Industries Ltd. - Key customers
  • 86: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 87: Teva Pharmaceutical Industries Ltd. - Overview
  • 88: Teva Pharmaceutical Industries Ltd. - Business segments
  • 89: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 90: Teva Pharmaceutical Industries Ltd. - Key customers
  • 91: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 92: Currency conversion rates for US$
  • 93: Research Methodology
  • 94: Validation techniques employed for market sizing
  • 95: Information sources
  • 96: List of abbreviations